echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > iScience: A potential way to combat inherited neurological disorders

    iScience: A potential way to combat inherited neurological disorders

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
       

       

    Image: Researchers at Mount Sinai Icahn School of Medicine and NCATS have discovered a compound that can reverse the effects
    of several neurodegenerative diseases called lysosomal storage disorders (LSDs) in patient cells and mice.
    LSDs are characterized by genetic defects that prevent the cell's lysosomes from breaking down and circulating fats, sugars and proteins that accumulate
    in the liver and brain.
    This can cause the energy-producing mitochondria to malfunction
    .
    These compounds increase the activity of TRAP1, a protein
    that helps mitochondria work properly.
    In the image above, lipid-filled lysosomes (red) from Nyman-Pick disease C1 cells are normalized when mitochondrial TRAP1 (green) is activated
    .

    Image credit: Ioannou Laboratory, Department of Genetics and Genomic Sciences, Icahn School of Medicine, Mount Sinai

    Scientists at the National Center for The Advancement of Translational Science (NCATS) at the Icahn School of Medicine in Mount Sinai, New York, and other researchers have reversed the effects
    of several life-threatening inherited neurodegenerative diseases— lysosomal storage disorders (LSDs) in patient cells and mice.

    The research team, led by Dr.
    Yannis Ioannou of Mount Sinai University and Dr.
    Juan Marugan, a translational scientist at the National Institutes of Health NCATS, restored the normal function
    of mitochondria and lysosomes by using new compounds they found capable of increasing TRAP1 activity.
    This protein helps the energy-producing mitochondria within the cell function properly
    .

    Dr Ioannou is Professor of Genetics and Genomic Sciences at Icahn School of Medicine at
    Mount Sinai.

    LSDs are characterized by genetic defects that prevent the lysosomes of cells from breaking down and circulating fats, sugars, and proteins, causing them to accumulate in organs, including the liver and brain
    .
    This can lead to mitochondrial malfunction, leading to further damage
    to these organs.

    What is this study trying to reveal? Researchers have long been looking for drugs that can affect lysosomals, trying to influence lysosomal storage diseases
    .
    This is a new way to treat these diseases
    .
    The increase in TRAP1 activity promotes mitochondrial protein folding, promoting proper balance
    of cells.
    These first-rate molecules activate TRAP1 in mitochondria and reduce storage in lysosomal storage
    diseases.

    Conclusion: The data suggest that mitochondrial TRAP1 is a potential new therapeutic target for a variety of diseases
    affecting the central nervous system.
    The researchers found that trap1 initiates a "dialogue" between mitochondria and lysosomes, which they determined is essential
    for restoring balance within the cell.
    Surprisingly, the researchers note that when TRAP1 is activated, a cascade is initiated, leading to the restoration
    of normal lysosomal function in lysosomal storage diseases.
    The defect that causes every lysosomal disease remains, but this crosstalk bypasses the genetic defect
    .
    The team showed that increasing the activity of TRAP1 in cells from patients with C1-type Niemann-Pick disease (a type of LSD) can correct lipid storage disorders and restore normal cholesterol levels
    .
    In addition, increased TRAP1 activity in cells from patients with other LSDs, such as Fabry, Farber and Wolman diseases, also corrected their respective lipid stores
    .
    (Niemann-Pick disease type C1 is a rare genetic disorder that affects the body's ability to
    metabolize fat within cells.
    ) )

    Why is this research important? The researchers say the findings could have implications for other neurodegenerative diseases with similar underlying causes, such as Parkinson's, amyotrophic lateral sclerosis and Alzheimer's
    .

    How was this research conducted? Dr.
    Ioannou and his colleagues developed a test method to measure the effect
    of compounds on C1-type Niemann-Pick disease.
    Working with Dr.
    Marugan and scientists at NCATS, they used NCATS's high-throughput screening equipment for testing, rapidly screening thousands of compounds
    .

    They found that compounds that activate TRAP1 get the mitochondria back to function and restart the circulating capacity of the lysosomes, helping to reduce fat
    in the lysosomes and cells.
    The researchers chemically modified the compounds that worked best and tested
    them further.

    Next: Scientists hope to learn more about how these compounds reverse the characteristics of lysosomal storage disease, which will help develop potential drug treatments
    .
    They also plan to continue refining the compounds and examining their effects in a variety of models, including their ability
    to influence more common neurological diseases such as Alzheimer's and Parkinson's disease.

    essay

    Activating mitochondrial TRAP1 stimulates mitochondrial-lysosomal crosstalk and corrects lysosomal dysfunction


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.